Scancell HoldingsSCNLF 16 Receivables Turnover is 0.00 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 839 Biotechnology companies, Scancell Holdings ranks better than 71.04% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Scancell Holdings's Revenue for the
six
months ended in Oct. 2025 was $0.00 Mil. Scancell Holdings's average Accounts Receivable for the
six
months ended in Oct. 2025 was $0.71 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Scancell Holdings Receivables Turnover Related Terms
Scancell Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNLF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Scancell Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a Receivables Turnover of 0.00 as of Oct. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #243 out of 839 companies in the Biotechnology industry, placing it in the top 29%.
Is Scancell Holdings' Receivables Turnover too high?
Scancell Holdings' current Receivables Turnover is 0.00. Based on the distribution chart, Scancell Holdings ranks #243 out of 839 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #243 out of 839 companies for Receivables Turnover. This puts Scancell Holdings in the upper half of its industry. The industry median Receivables Turnover is 5.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Scancell Holdings' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Receivables Turnover is 0.00 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
16GF Score
Get the complete analysis for SCNLF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
